Skip to content
‹ Back to IndustriesSciences

Why You Shouldn’t Be Using ‘Conventional’ Methods for Unconventional Drilling

The Sciences Podcast explores the use of big data for both conventional and unconventional reservoirs with insights from geoscientists at Ikon Science. Gabi D’Aubeterre and Yoryenys Del Moro discuss the challenges of unconventional reservoirs, highlighting the need for advanced data techniques. Unconventional drilling requires changing traditional methods to effectively extract hydrocarbons.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · DrillingGabi D’aubeterre PodcastGeopredictionGeoscientist
Share
Why You Shouldn’t Be Using ‘Conventional’ Methods for Unconventional Drilling

Key takeaways

01

Ikon Science experts emphasize the necessity to change traditional methods when dealing with unconventional reservoirs.

02

Big data including seismic and well information is crucial for optimizing production in unconventional drilling.

03

Unconventional reservoirs require advanced techniques to effectively extract hydrocarbons, as traditional trapping mechanisms are absent.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

On this episode of the Sciences Podcast, host Tyler Kern dug deep, so to speak, on the topic of using big data for conventional and unconventional reservoirs with two geoscientists from Ikon Science. Today’s guests are Gabi D’Aubeterre], Americas support team manager, and Yoryenys Del Moro, regional product champion for wells.

Del Moro said current methods are just scratching the surface of what kind of production is possible.

“To get more production, … we need to use more data, including seismic and well information,” she said.

Ikon Science develops pioneering GeoPrediction software technology and solutions to help customers have better hit rates and faster production with reduced cost and cycle time. The quantitative interpretation of seismic and well data has been widely successful for conventional operations around the world but lags in unconventional reservoirs, D’Aubeterre and Del Moro said.

“When it comes to unconventional reservoirs, we need to change our mindset from what we’ve done traditionally,” D’Aubeterre said.

Unconventional reservoirs pose a unique challenge for geoscientists. While the rocks in conventional reservoirs effectively traps oil and gas until it’s drilled, this same trapping mechanism is not present in more difficult unconventional plays. In a conventional reservoir, the type of rock (usually a sandstone) traps the hydrocarbon effectively within its porous space, but this is not the case for unconventional reservoirs.

“In an unconventional reservoir, the hydrocarbons do not flow naturally and are trapped within the rock, within low permeability and low porosity units” D’Aubeterre said. Fracturing the rock and shale to extract that oil and gas makes a challenge for geoscientists and engineers.

Del Moro agreed, saying complications exist when geoscientists and engineers look to fracture the right area of rock for the right natural resource to produce hydrocarbons.

“So you need to apply the techniques that allow you to define and detect what you’re looking for in the shales, fractures, and natural fracture zones,” Del Moro said, explaining seismic data allows you to do that.

D’Aubeterre and Del Moro shared specific examples of quantitative interpretation of seismic and well data in unique settings and how the machine learning and integration.

Read more on the Ikon Science Website.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

SR-Tiget gene therapy families average six months in Milan and years of lab tests

SR-Tiget gene therapy families average six months in Milan and years of lab tests

Gene therapy at Milan’s SR-Tiget includes a family support programme that helps relatives manage months-long stays (often around six months) for treatment, while a regulated lab can track patient samples for up to 20 years. Follow-up visits can outnumber new treatments, adding to the long-term workload.

  • 01In 2025, SR-Tiget's family programme coordinated 133 follow-up visits against 17 new treatments. That gap keeps widening because each patient enters roughly 15 years of twice-yearly checkups.
  • 02At SR-Tiget, the average family spends six months in Milan, and the child's samples can keep reaching the lab for as long as twenty years.
  • 03Any gene therapy service has to answer one question: who tells the lab when a child's fever pushes a blood draw from morning to afternoon? In Milan, research nurses own that handoff.

Nov 16, 2026

Two photonic AI components reach outside testers—on limits

Two photonic AI components reach outside testers—on limits

Kopin is expanding microLED manufacturing in Westborough, Massachusetts, which could add up to 80 jobs over five years. Its microLEDs will go to military displays and to Neural I/o, an interconnect that sends AI data as light. In the same news round-up, Q.ANT and IONOS opened a photonic processor pilot where approved applicants can run their own workloads.

  • 01Two photonic approaches tied to AI’s power problem reached testable hardware this month: PsiQuantum’s 8×8 optical switch samples and Q.ANT’s second-generation processor via an IONOS bare-metal pilot in Germany.
  • 02PsiQuantum is sending samples of an 8×8 demonstration optical circuit switch to selected prospective customers, giving buyers hardware they can test even though commercial products and full specs are still pending.
  • 03Staffing may not keep up with demand: a 2023 Applied Optics study projected US demand for 42,000 new middle-skilled photonics workers by 2030, and expansions like Kopin's could draw from that same pool.

Nov 15, 2026

Lilly breaks ground on a $5B Virginia bioconjugate plant; first building expected in 2030

Lilly breaks ground on a $5B Virginia bioconjugate plant; first building expected in 2030

Lilly’s Goochland County site is designed to make APIs and finished medicines on one campus. Virginia Business reported the first building is expected to open in 2030.

  • 01Goochland’s pilot-scale training center is slated to open in 2028, two years before Lilly expects its first production building in 2030—signaling workforce readiness as the earliest milestone at Lilly’s first dedicated, fully integrated API and drug product facility for its bioconjugate platform and monoclonal antibody portfolio.
  • 02For anyone tracking new ADC supply, Goochland is a later story: Lilly expects to open the first building in 2030 and the second in 2031.

Nov 15, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

S
Sciences
GD
Gabi D’Aubeterre

Americas Support Team Manager

Ikon Science

YD
Yoryenys Del Moro

Regional Product Champion for Wells

Ikon Science

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512